Targets › NGFR
2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 2; Ophthalmology, Oncology; next expected readout Mar 2027.
Low affinity receptor which can bind to NGF, BDNF, NTF3, and NTF4. Forms a heterodimeric receptor with SORCS2 that binds the precursor forms of NGF, BDNF and NTF3 with high affinity, and has much lower affinity for mature NGF and BDNF. Plays an important role in differentiation and survival of specific neuronal populations during development (By similarity). (UniProt, P08138)
Open in Phaseline: the race on NGFR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of South Florida | Acoltremon 0.003% ophthalmic solution Recombinant human nerve growth factor (NGF) | NGFR | Phase 4 | Ocular Surface Disease | Mar 2027 |
| Benedetto Falsini | CHF6467 Nerve growth factor (NGF) agonist; binds trkA (NTRK1) receptor with high affinity and p75N | NGFR, NTRK1 | Phase 2 | Optic Pathway Glioma | Jun 2027 |
Ocular Surface Disease (1) Optic Pathway Glioma (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.